Type 2 Diabetes Market Driven by Rising Global Prevalence and Advancements in GLP-1 Therapies | Novo Nordisk A/S, Eli Lilly and Company., Sanofi, Pfizer Inc.

Type 2 Diabetes Market Size reached US$ 61.50 billion in 2024 and is expected to reach US$ 124.26 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025-2033.

Type 2 Diabetes Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With rising prevalence, technological advancements

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/type-2-diabetes-market?ophp

Type 2 Diabetes is a chronic condition characterized by insulin resistance and elevated blood sugar levels. The global market is growing steadily, driven by rising obesity, sedentary lifestyles, and aging populations. Novel drug classes like GLP-1 receptor agonists, SGLT2 inhibitors, and fixed-dose combinations are fueling innovation, while digital monitoring tools and insulin delivery systems add value.

Type 2 Diabetes Market Competitors Overview:

Novo Nordisk A/S, Eli Lilly and Company., Sanofi, Pfizer Inc., Johnson & Johnson Services, Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Viatris Inc., and Teva Pharmaceutical Industries Ltd., among others.

Important Industry Updates of 2023, 2024 and 2025:

✅ In April 2025, Eli Lilly and Company announced that its investigational drug orforglipron has shown positive results in phase 3 clinical trials, which are evaluating safety and efficacy in type 2 diabetes patients. Orforglipron is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist, which is taken once daily without any food or water restrictions. In the phase 3 trials, Orforglipron 12 mg has reduced 1.6% A1C from a baseline of 8.0%.

✅ In April 2025, FDA Approves Generic Liraglutide for Type 2 Diabetes has announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Victoza (liraglutide) for Type 2 Diabetes.

GLP-1 Receptor Agonist ➨Manufacturer ➨Sales (US$ Million) in 2024

Ozempic ➨Novo Nordisk A/S ➨17,461.62
Mounjaro ➨Eli Lilly and Company. ➨11,540.10
Trulicity ➨Eli Lilly and Company. ➨5,253.50
Rybelsus ➨Novo Nordisk A/S ➨3,380.98
Victoza ➨Novo Nordisk A/S ➨795.44

Methodology and Scope

The Type 2 Diabetes Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/type-2-diabetes-market?ophp

Type 2 Diabetes Market Segments Overview:

∎ By Drug Type (Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors, Alpha-glucosidase Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Sodium-glucose Transporter 2 (SGLT2) Inhibitors, Meglitinides, Sulfonylureas, Thiazolidinediones, Biguanides (Metformin), and Others)
∎ By Gender (Male and Female)
∎ By Route of Administration (Oral and Parenteral)
∎ By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

The GLP-1 receptor agonists segment will hold the highest market share due to its dual benefits in blood sugar control and weight management, along with proven cardiovascular safety

Regional Overview for Type 2 Diabetes Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

North America holds the largest share of the type 2 diabetes market, driven by high disease burden, early adoption of advanced therapies like GLP-1 analogues, and strong healthcare infrastructure. Asia Pacific is the fastest growing region due to rising d

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=type-2-diabetes-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Type 2 Diabetes market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Type 2 Diabetes market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.